These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3120167)

  • 1. Growth hormone responses to hp GRF 1-44 amide, bromocriptine and stress in acromegaly are correlated.
    Belchetz PE
    Postgrad Med J; 1987 Apr; 63(738):241-4. PubMed ID: 3120167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone releasing factor-test in acromegaly: comparison with other dynamic tests.
    Losa M; Schopohl J; Stalla GK; Müller OA; von Werder K
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):99-109. PubMed ID: 3931944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
    Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
    J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine.
    Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG
    J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormalities of growth hormone release in response to human pancreatic growth hormone releasing factor (GRF (1-44) ) in acromegaly and hypopituitarism.
    Wood SM; Ch'ng JL; Adams EF; Webster JD; Joplin GF; Mashiter K; Bloom SR
    Br Med J (Clin Res Ed); 1983 May; 286(6379):1687-91. PubMed ID: 6405935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor.
    Thorner MO; Perryman RL; Cronin MJ; Rogol AD; Draznin M; Johanson A; Vale W; Horvath E; Kovacs K
    J Clin Invest; 1982 Nov; 70(5):965-77. PubMed ID: 6290540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of growth hormone-releasing factor (GRF) and dopamine on growth hormone (GH) secretion in acromegaly.
    Giusti M; Lomeo A; Mazzocchi G; Mignone D; Sessarego P; Monachesi M; Giordano G
    J Endocrinol Invest; 1985 Jun; 8(3):203-6. PubMed ID: 3928732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interrelationship between the effects of somatostatin and human pancreatic growth hormone-releasing factor on growth hormone release by cultured pituitary tumor cells from patients with acromegaly.
    Lamberts SW; Verleun T; Oosterom R
    J Clin Endocrinol Metab; 1984 Feb; 58(2):250-4. PubMed ID: 6141175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
    Ishibashi M; Yamaji T
    J Clin Invest; 1984 Jan; 73(1):66-78. PubMed ID: 6140273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone releasing factor induces prolactin secretion in acromegalic patients but not in normal subjects.
    Losa M; Schopohl J; Müller OA; von Werder K
    Acta Endocrinol (Copenh); 1985 Aug; 109(4):467-73. PubMed ID: 3929513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
    Shibasaki T; Hotta M; Masuda A; Imaki T; Obara N; Hizuka N; Takano K; Wakabayashi I; Demura H; Ling N
    J Clin Endocrinol Metab; 1986 Jul; 63(1):167-73. PubMed ID: 2872226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential uses of human pancreatic growth hormone-releasing factor 1-44 amide.
    Belchetz PE; Weldon SF; Davis JC; Diver MJ; Smith CS; Harris F
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):201-8. PubMed ID: 6432378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Suppression by dopamine of GH release induced by GRF in a case of acromegaly].
    Matsubara M; Odagaki E; Morioka T
    Nihon Naibunpi Gakkai Zasshi; 1987 Mar; 63(3):193-7. PubMed ID: 3111898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly.
    Ishibashi M; Yamaji T
    J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of effect of muscarinic cholinergic blockade on the GH responses to GRF 1-29 and TRH in acromegalic subjects.
    Jordan V; Dieguez C; Valcavi R; Artioli C; Portioli I; Rodriguez-Arnao MD; Gomez-Pan A; Hall R; Scanlon MF
    Clin Endocrinol (Oxf); 1986 Apr; 24(4):415-20. PubMed ID: 2874906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acromegaly due to ectopic growth hormone (GH)-releasing hormone (GHRH) production: dynamic studies of GH and ectopic GHRH secretion.
    Barkan AL; Shenker Y; Grekin RJ; Vale WW; Lloyd RV; Beals TF
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1057-64. PubMed ID: 3093517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly].
    Gasińska T; Nowak S
    Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretory mechanisms of growth hormone (GH)-releasing peptide-, GH-releasing hormone-, and thyrotropin-releasing hormone-induced GH release in patients with acromegaly.
    Hanew K; Utsumi A; Tanaka A; Ikeda H; Yokogoshi Y
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3578-83. PubMed ID: 9768668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ovine corticotrophin-releasing factor and hydrocortisone on growth hormone secretion by pituitary adenoma cells of acromegaly in culture.
    Ishibashi M; Hara T; Tagusagawa Y; Fukushima T; Numata H; Hori T; Yamaji T
    Acta Endocrinol (Copenh); 1984 Aug; 106(4):443-7. PubMed ID: 6332444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.